Trial Readiness of Cavernous Malformations With Symptomatic Hemorrhage, Part I: Event Rates and Clinical Outcome.
Kelly D FlemmingHelen KimStephanie HageJay MandrekarSerena KinkadeRomuald GirardMichel T TorbeyJudy HuangJohn HustonYunhong ShuGiuseppe LanzinoReed G SelwynBlaine L HartMarc C MabrayJames FeghaliHaris I SairJared NarvidJanine M LupoJustine LeeAgnieszka StadnikRoberto J Alcazar-FelixRobert ShenkarKaren LaneNichole McBeeKevin TreineNoeleen OstapkovichYing WangRichard ThompsonJaroslaw AronowskiTimothy J CarrollDaniel F HanleyIssam A AwadPublished in: Stroke (2023)
We report SH rate, functional, and patient-reported outcomes in trial-eligible cerebral cavernous malformation with SH patients. Functional outcomes and patient-reported outcomes generally improved over 2 years. No score change was highly sensitive or specific for SH and could not be used as a primary end point in a trial.
Keyphrases
- patient reported outcomes
- study protocol
- phase iii
- phase ii
- clinical trial
- randomized controlled trial
- end stage renal disease
- open label
- newly diagnosed
- subarachnoid hemorrhage
- chronic kidney disease
- prognostic factors
- mass spectrometry
- living cells
- fluorescent probe
- blood brain barrier
- cerebral ischemia
- single molecule
- double blind